Register for our free email digests:
An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
An M.D. is preferred for position that would run CDER in director's absence and oversee 'major programs' at the Center.
At inconveniently timed NORD conference, the former CDER deputy center director finds himself unable to speak for either FDA or the Pharmaceutical Research and Manufacturers of America.
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
US FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee votes in favor of efficacy of proposed glaucoma treatment, but several say only in patients with baseline intraocular pressure less than 25 mmHg.
Proposed treatment for elevated intraocular pressure would be first in new rho-associated protein kinase inhibitor class.